Location: Virtual
Gene and nucleic acid therapies are increasingly being established as important modalities for the next generation of medicine. However, in vivo delivery challenges currently limit their full potential to achieve more widespread clinical use. Scientific innovations are needed to improve the efficiency, tissue biodistribution, cellular/ tissue selectivity, payload capacity, and immunogenicity to enable therapies with enhanced safety and efficacy profiles.
In this webinar, our panel of scientific experts and entrepreneurs will highlight some of the key delivery challenges facing the field of gene and nucleic acid therapeutics and will discuss select scientific innovations that are being undertaken with the aim to address these challenges. Discussion topics will include both viral and non-viral systems for delivery of DNA, mRNA, siRNA/ASO payloads in addition to cell/tissue specific targeting approaches.
DPDS (Discovery, Product Development and Supply) of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen)’s external innovation team invites innovators with potential solutions to these challenges to apply for an opportunity to meet 1-on-1 to discuss their innovative solutions.
Areas of particular interest include unmet needs in:
– Enhanced delivery to retina, cochlea, brain, kidney, and heart
– Cell targeting moieties for selective cellular uptake
– Lipid nanoparticles with cell targeting properties
– AAV capsid engineering for improved biodistribution
– Approaches to limit immune surveillance and response